Follow us on Twitter
This page is updated frequently with new Anxiety-related patents. Subscribe to the Anxiety RSS feed to automatically get the update: related Anxiety RSS feeds.
Subscribe to updates on this page: Anxiety RSS
|| List of recent Anxiety-related patents
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which is useful for the treatment or prevention of diseases such sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension, and of which the action relies on an orexin (ox) receptor antagonistic activity.. .
|Neuroactive steroid compositions and methods of use therefor|
Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury.
|Protein-bound tryptophan food composition|
A composition comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, which plant source has been processed to at least partially remove oil contained therein to yield said meal having a natural source of tryptophan greater than its plant source, a carbohydrate source having a high glycemic index and a physiologically-acceptable diluent or carrier therefor for inducing sleep, alleviating an anxiety disorder, depression, obsessive compulsive aggression, chronic pain or eating disorder, in a human in need thereof, wherein said composition is in the form of a food bar further comprising a puffed cereal. The composition provides improved sleep characteristics..
|1, 2, 4-triazolone derivative|
The present invention provides a 1,2,4-triazolone derivative represented by formula (1a) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.. .
|Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion|
A system and method for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to treat mood and/or anxiety disorders uses an implantable system control unit (scu), specifically an implantable signal/pulse generator (ipg) or microstimulator with one or more electrodes in the case of electrical stimulation, and an implantable pump with one or more catheters in the case of drug infusion. In cases requiring both electrical and drug stimulation, one or more scus are used.
|Glycine transporter inhibiting substances|
The present invention aims to provide novel compounds of formula [i] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder:. .
|Pyrimidones for treatment of potassium channel related diseases|
The present invention relates to compounds of formula i as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of formula i or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.. .
|Methods for targeting deep brain sites to treat mood and/or anxiety disorders|
The present invention relates to a method of identifying a target such as within the subgenual area by measuring neuronal activity in response to a stimulus. Once the target is identified, it can be stimulated to treat a neurological disorder, such as a mood disorder or an anxiety disorder..
|Pharmaceutical composition comprising n-acetyl-l-cysteine or its derivatives for treating anxiety disorder|
The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising n-acetyl-l-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, n-acetyl-l-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia..
|Piperidinyl pyrimidine amides as kv7 potassium channel openers|
The present invention relates to compounds of formula (i) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of formula (i) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.. .
|Herbal composition for preventing and/or treating anxiety related conditions|
The present invention relates to herbal compositions for the treatment and/or prevention of anxiety disorders or stress. These compositions comprise hawthorn fruit (shan zha), light wheat grain (fu xiao mai) and lilly bulb (bai hi) in amounts which are effective to treat anxiety conditions.
|S-adenosylmethionine formulations with enhanced bioavailability|
Provided herein are compositions and methods to enhance the absorption of s-adenosylmethionine (same) and methods of treating various disorders or diseases using non-parenteral same formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g.
A compound represented by formula [i] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group ii metabotropic glutamate (mglu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.. .
Provided is a novel compound represented by formula [i] or a pharmaceutically acceptable salt thereof having antagonistic activity against group ii metabolism-type glutamic acid (m-glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like..
|Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride|
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
|Heterocyclic compounds for the treatment of neurological and psychological disorders|
Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
|Kennel with automatically opening door|
The present invention seeks to prevent damage to property resulting from an animal's separation anxiety which occurs when a pet owner departs, while minimizing the period of time the dog is confined. The device incorporates an automatically releasing door of a kennel or leash.
|Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders|
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone.
|Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract|
A pomegranate pulp extract is disclosed. The pomegranate pulp extract is effective in relieving women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders due to the presence of a large amount of ellagic acid.
|Method of treating binge eating disorder|
The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in adhd and add patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in adhd and add patients.
Popular terms: [SEARCH]
Follow us on Twitter
This listing is a sample listing of patents related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.